Other substances

CoV-X2

An anti-RBD (SARS-CoV-2 Spike) bispecific antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

CoV-X2 is a human-derived IgG-like bispecific fusion antibody, which potently binds to SARS-CoV-2 Spike protein RBD. It is capable to simultaneously bind two different epitopes on a single RBD or two RBDs on different Spike trimer subunits (regardless of their conformation). It potently neutralizes various SARS-CoV-2 strains (WT (Wuhan), B.1 (D614G), B.1.1.7 (United Kingdom), P.1 (Brazil), or B.1.351 (South Africa)). Experimentally, it protected a mouse model from SARS-CoV-2 (a Czech Republic isolate) infection. Viral evasion from this bispecific antibody was not observed (De Gasparo et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
Spike protein Biophysical assay Animal model In vitro Antibody In silico 		in silico; in vitro biophysical assay; 293T-ACE2 cells; Vero E6 cells; AAV-hACE2 C57Bl/6NCrl mice; SARS-CoV-2 Spike pseudoviruses (various); SARS-CoV-2 strains WT, B.1, B.1.1.7, P.1, B.1.351, and SARS-CoV-2/human/Czech Republic/951/2020 42.78

The antibody is capable to simultaneously bind two different epitopes on a single RBD or two RBDs on different Spike trimer subunits (regardless of their conformation). It potently neutralized various SARS-CoV-2 strains (WT (Wuhan), B.1 (D614G), B.1.1.7 (United Kingdom), P.1 (Brazil), or B.1.351 (South Africa)) with IC50s ranging from 12 nM (B.1.351) to 0.2 nM (B.1 or B.1.1.7) in vitro. The antibody administered prior to or after a viral challenge (SARS-CoV-2/human/Czech Republic/951/2020) protected a mouse model (expressing human ACE2 in the respiratory tract) from weight loss, lung inflammation and lung tissue damage and decreased the viral burden. Viral evasion from this bispecific antibody was not observed (a mutation rendering one of the paratopes ineffective was observed, but the activity of the other was sufficient for the antibody to remain protective.

 Mar/25/2021
Export (.csv)